WOMEN’S-ENTREPRENEURSHIP
13.9.2023 20:19:31 CEST | Business Wire | Press release
In alignment with the 78th session of the United Nations General Assembly, the Women’s Entrepreneurship Accelerator (WEA) is proud to announce a pivotal event spotlighting the pressing gap in financing for women-led businesses. This initiative is a collaborative effort with WEA-participating UN agencies, Mary Kay Global, Yildiz Holding, and the Women Entrepreneurs Act initiative (WE Act) of the Women20 (W20) countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230913108266/en/
Titled “Inclusive Capital: Empowering Women Entrepreneurs on a Global Scale,” the WEA’s event at UNGA78 is a pivotal event spotlighting the pressing gap in financing for women-led businesses and aiming to foster dialogue among stakeholders in the women's entrepreneurship ecosystem. (Credit: Women’s Entrepreneurship Accelerator)
“Inclusive Capital: Empowering Women Entrepreneurs on a Global Scale”
Conference Room 2, United Nations Headquarters, NYC
Thursday 21 September 2023. Time: 6:00 pm – 8:00 pm ET
Register here
The event aims to foster dialogue among stakeholders in the women's entrepreneurship ecosystem. Discussions will revolve around the financial challenges women entrepreneurs face, the significance of inclusive investing, and the need for institutional and corporate entities to adopt a gender-inclusive perspective in their decision-making processes.
“Through the inception of the Women’s Entrepreneurship Accelerator, Mary Kay has helped carve a new path of intervention for the private sector,” said Deborah Gibbins, Chief Operating Officer, and Chief Financial Officer of Mary Kay Inc. “WEA is a groundbreaking partnership vehicle where the United Nations, public and private sectors, civil society organizations, and policy experts work together to transform the world WITH and FOR women entrepreneurs.”
The evening will commence with welcoming remarks from the executive leadership of UN Women followed by an introduction from Fulya Fraser, Chief Growth Officer at Pladis – part of the Yildiz Holding family of companies.
Two panel sessions will delve deep into the topics at hand:
- Accelerating Agenda 2030 through Women Entrepreneurship - Moderated by Virginia Littlejohn, Global Coordinator for Women Entrepreneurs Act (WE Act) designed to drive W20 action and implementation. The session will explore the "Trillion-dollar Opportunity in Supporting Women Entrepreneurs" and the potential economic impact if women-led businesses surmount financial barriers. Esteemed speakers include executive leaders from WEA UN partner agencies.
- Global Action for Women's Entrepreneurship - This session will spotlight major projects and programs in women entrepreneurship, featuring insights from international development leaders like Adriana Carvalho (W20Brazil), Wendy Teleki (World Bank), Marie-Christine Oghly (Femmes Chefs d’ Entreprise Mondiales - FCEM); Catherine Bosshart (Business and Professional Women - BPW), Anne Ravanona (Global InvestHER), Deborah Gibbins, Mary Kay Global, Lamia Kamal-Chaoui (Organisation for Economic Co-operation and Development - OECD).
The event's keynote will be delivered by Shazi Visram, Founder and CEO of Happy Family brands.
Registration is open until Sunday 17 September 2023 at 11:59 p.m. ET for in-person attendance at the UN Headquarters, NYC. For those unable to attend, the event will be streamed live on the United Nations Web TV website.
For more information and to register, click here.
About the Women’s Entrepreneurship Accelerator
The Women’s Entrepreneurship Accelerator (WEA) is a multi-stakeholder partnership on women’s entrepreneurship established during UNGA 74. It convenes six UN agencies, International Labour Organization (ILO), International Trade Centre (ITC), International Telecommunication Union (ITU), United Nations Development Programme (UNDP), United Nations Global Compact (UNGC), UN Women and Mary Kay Inc. to empower 5 million women entrepreneurs by 2030.
The ultimate goal of the initiative is to maximize the development impact of women entrepreneurship in achieving the Sustainable Development Goals (SDGs) by creating an enabling eco-system for women entrepreneurs around the world. The Accelerator exemplifies the transformational power of a multi-partnership of unique magnitude to harness the potential of women entrepreneurs.
Learn more at we-accelerate. Follow us: Twitter/X (We_Accelerator), Instagram (@we_accelerator), Facebook (@womensentrepreneurshipaccelerator), LinkedIn (@womensentrepreneurshipaccelerator)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230913108266/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom